ATAI vs. NAMS, TWST, DNLI, KNSA, AGIO, VCEL, CGON, RXRX, BEAM, and BLTE
Should you be buying atai Life Sciences stock or one of its competitors? The main competitors of atai Life Sciences include NewAmsterdam Pharma (NAMS), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kiniksa Pharmaceuticals International (KNSA), Agios Pharmaceuticals (AGIO), Vericel (VCEL), CG Oncology (CGON), Recursion Pharmaceuticals (RXRX), Beam Therapeutics (BEAM), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry.
atai Life Sciences vs. Its Competitors
NewAmsterdam Pharma (NASDAQ:NAMS) and atai Life Sciences (NASDAQ:ATAI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.
atai Life Sciences has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -397.45%. NewAmsterdam Pharma's return on equity of -37.34% beat atai Life Sciences' return on equity.
atai Life Sciences has lower revenue, but higher earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than atai Life Sciences, indicating that it is currently the more affordable of the two stocks.
NewAmsterdam Pharma presently has a consensus target price of $42.89, indicating a potential upside of 104.04%. atai Life Sciences has a consensus target price of $9.00, indicating a potential upside of 239.62%. Given atai Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe atai Life Sciences is more favorable than NewAmsterdam Pharma.
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. Comparatively, 28.4% of atai Life Sciences shares are owned by institutional investors. 20.8% of NewAmsterdam Pharma shares are owned by company insiders. Comparatively, 26.8% of atai Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, NewAmsterdam Pharma had 1 more articles in the media than atai Life Sciences. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 3 mentions for atai Life Sciences. NewAmsterdam Pharma's average media sentiment score of 0.80 beat atai Life Sciences' score of 0.33 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.
NewAmsterdam Pharma has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, atai Life Sciences has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.
Summary
atai Life Sciences beats NewAmsterdam Pharma on 10 of the 17 factors compared between the two stocks.
Get atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
atai Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ATAI) was last updated on 7/16/2025 by MarketBeat.com Staff
